ArticleScientific reports2025
Evaluation of thymidine kinase 1 and folate receptor alpha as potential biomarkers in prostate cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a widespread malignancy with high mortality rates. Therapeutic success depends on clinical biomarkers for early detection and progression of the disease. The study aimed to assess the potential role of Thymidine Kinase one (TK1) and folate receptor alpha (FORα) in prostate cancer. Forty-five newly diagnosed prostate cancer patients, and 45 age matched apparently healthy males were included. Serum levels of TK1 and FORα were measured using enzyme-linked immunosorbent assay (ELISA) technique. TK1 and FORα were significantly increased in prostate cancer patients compared to the control group (mean 28.11pg/ml vs. 15.66 pg/ml, p-value < 0.001) and (median 1686.4 pg/ml vs. 437.2 pg/ml, p-value < 0.001) respectively. At a cutoff level ˃22.1 pg/ml, TK1 showed 91.11% sensitivity, 88.89% specificity and AUC = 0.973 (95% CI: 0.945-0.999). FORα showed moderate discriminatory power with 73.33% sensitivity and 88.89% specificity, AUC was 0.770 (95% CI: 0.661-0.879) at cutoff level ˃918.16 pg/ml. Combining TK1 with total PSA markedly improved the diagnostic accuracy (sensitivity 95.56%, specificity 97.78%). TK1 showed significant positive correlation with Gleason score, WHO grade and presence of metastasis at p < 0.001 each. TK1 & FORα could serve as biomarkers for prostate cancer diagnosis and prognosis offering a novel treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.